Zenith Epigenetics Corp. is a research and development biotechnology company focused on new and innovative drugs by leveraging its proprietary epigenetics platform. The company's epigenetic drug discovery platform functions by inhibiting BET bromodomains, having the potential to impact multiple diseases including autoimmune and oncology.

Learn More

News Highlights

Zenith Epigenetics Corp. Centralizes Head Office and Laboratory

We are pleased to announce the relocation and centralization of our main office and laboratory.

Effective May 1, 2014, our Midpark Way office and 31st Street laboratory in Calgary have relocated to:

300, 4820 Richard Road SW

Calgary, AB T3E 6L1

Tel: 587.390.7865 Fax: 403.256.8495

(Telephone and fax numbers remain unchanged)

If you have any questions, do not hesitate to contact us at info@zenithepigenetics.com.

Best regards,

Zenith Epigenetics Management

Read More

Zenith Epigenetics Closes $8 million Private Placement

CALGARY, March 14, 2014 - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has closed a private placement of 8,000,000 common shares at a price of US$1.00 per share for gross proceeds of US$8,000,000 (the "Private Placement") to Eastern Capital Limited ("Eastern") and NGN BioMed Opportunity II, L.P. ("NGN"). Eastern and NGN subscribed for 6,000,000 and 2,000,000 common shares, respectively. The shares are subject to a four month hold period.

After giving effect to the Private Placement, Eastern and NGN hold 19,200,000 and 8,769,339 common shares, respectively, of Zenith, representing approximately 22.9% and 10.5%, respectively, of Zenith's issued and outstanding common shares. Eastern and NGN also hold 2,048,640 and 1,683,665 common share purchase warrants of Zenith, respectively.

Read More

EpiCongress Boston 2014 (July 22 - 24)

We are proud to announce that we are the Lead Sponsor for this conference. 

Read More Add This to my Calendar

Sign Up For Updates

Please submit your name and email for latest news. To unsubscribe from alerts, please click here.

Email Address*